Osteoporosis from androgen deprivation therapy in prostate cancer treatment.
BACKGROUND
Bone complications from metastatic disease in prostate cancer have been well documented. Osteoporosis from androgen deprivation therapy (ADT) can further impair quality of life in this already susceptible age group.


OBJECTIVE
We aimed to assess the intermediate and long term effects of ADT on bone density and the development of osteoporosis in men with prostatic cancer, and outline some practical assessment, management and treatment options.


CONCLUSIONS
Osteoporosis, exacerbated by the use of ADT, reduces both the survival and quality of life of men who may otherwise live for many years with their well controlled prostate cancer. Hence, both preventive and treatment options should be explored and tailored to the individual, including lifestyle modifications (exercise, smoking cessation), vitamin D and calcium supplementation, and the use of bisphosphonates.
McLeod
Nicholas
N
Department of Urology, Port Macquarie Base Hospital, New South Wales.
Huynh
Chi Can
CC
Rashid
Prem
P
D015502:Absorptiometry, Photon; D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects*; D002136:Calcium, Dietary / Q000627:therapeutic use; D019587:Dietary Supplements; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011966:Receptors, LHRH / Q000037:antagonists & inhibitors; D012307:Risk Factors; D014807:Vitamin D / Q000627:therapeutic use
D000726:Androgen Antagonists; D002136:Calcium, Dietary; D004164:Diphosphonates; D011966:Receptors, LHRH; D014807:Vitamin D